Physician profile
Usha Venkatraj
NPI 1760409668
$1,540.31
in general payments reported to CMS, 2019-2025
22 companies · $52.61 in 2025
The $52.61 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $208 · 2021: $27.41 · 2022: $54.23 · 2023: $351 · 2024: $489 · 2025: $52.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $892.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $892.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $273.35 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $263.36 | 2019-2024 | Krazati, Opdualag, Opdivo |
| Pfizer INC. | $211.76 | 2019-2024 | |
| Seagen INC. | $171.12 | 2019-2023 | Padcev, Adcetris |
| Abbvie INC. | $84.16 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.01 | 2019 | |
| Array Biopharma INC | $73.61 | 2019-2024 | Braftovi, Lorbrena, Mektovi |
| Astellas Pharma US INC | $54.01 | 2023-2024 | Xtandi |
| Janssen Biotech, INC. | $46.52 | 2019-2023 | Erleada |
| Astrazeneca Pharmaceuticals LP | $38.35 | 2023-2024 | Enhertu, Tagrisso |
| Pharmacyclics LLC, An Abbvie Company | $36.05 | 2022 | |
| Merck Sharp & Dohme LLC | $29.87 | 2023-2024 | Keytruda, Lynparza |
| Karyopharm Therapeutics INC. | $23.98 | 2024 | Xpovio |
| Mirati Therapeutics, INC. | $21.47 | 2024 | Krazati |
| Incyte Corporation | $21.21 | 2024 | Jakafi |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $18.77 | 2024 | Reblozyl |
| Glaxosmithkline, LLC. | $18.68 | 2023 | Ojjaara |
| Bayer Healthcare Pharmaceuticals INC. | $17.34 | 2024 | |
| Amgen INC. | $16.20 | 2019 | |
| Genentech USA, INC. | $14.02 | 2020 | |
| Exelixis INC. | $13.55 | 2024 | Cabometyx |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Usha Venkatraj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.